Chang Liu

Chang Liu

Auto-generated profile, based on publicly available information

Chang Liu

National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Harbin, 150040, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2018 in Molecular Genetics and Genomics
Verified
Journal Article
Closed access
PDF file
SXSha Xiao
Sha Xiao
MZMing Zhang
Ming Zhang
CLChang Liu
Chang Liu
DWDeling Wang
Deling Wang

10 August 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZWZong-Wei Wang
Zong-Wei Wang
CLChang Liu
Chang Liu
AZAi-Hua Zhang
Ai-Hua Zhang
GYGuang-Li Yan
Guang-Li Yan
HSHui Sun
Hui Sun
XWXijun Wang
Xijun Wang

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
Dancai FanDancai Fan
Dancai Fan
CLChang Liu
Chang Liu
LLLi Li
Li Li
CLCheng Lu
Cheng Lu
NZNing Zhao
Ning Zhao
ALAiping Lu
Aiping Lu
The Chinese formula Pien Tze Huang (PZH) has been used to treat hepatocellular carcinoma (HCC) and showed positive clinical effects. However, the antitumor mechanism of PZH in HCC remains unclear. In this study, HCC xenograft Balb/c mice were treated with PZH; then, proteomics detection and Ingenuity Pathway Analysis (IPA) were used to analyze the differentiated phosphorylated proteins in tumor tissues. The results indicated that PZH could inhibit tumor weight by 50.76%. Eighty‐four upregulated and 11 downregulated phosphorylated proteins were identified in PZH‐treated mice. Twenty signaling pathways were associated with inflammation (including the IL‐6 and TNFR1/2 pathways), cancer growth (including the p53 and FAK pathways), and the cell cycle (including the G2/M and G1/S checkpoint regulation pathways). Moreover, TNF‐ α , IL‐6, and several typical differentially expressed phosphorylated proteins (such as p‐CCNB1, p‐FOXO3, and p‐STAT3) in tumor tissues, tumor cell viability, and cell cycle arrest assay in vitro further verify the results of IPA. These results revealed that PZH achieved antitumor activity in HCC; the underlying mechanisms of which were mainly through regulating the inflammation‐associated cytokine secretion, cancer growth pathways, and induction of G2/M arrest. These data provided the potential molecular basis for PZH to act as a therapeutic drug or a supplement to chemotherapy drugs for human HCC in the future.

11 October 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
XWXiaohua Wan
Xiaohua Wan
CLChang Liu
Chang Liu
TOThomas Olson
Thomas Olson
XCXiankun Chen
Xiankun Chen
WLWeihui Lu
Weihui Lu
WJWei Jiang
Wei Jiang
Background: As demand for cardiopulmonary exercise test using a supine position has increased, so have the testing options. However, it remains uncertain whether the existing evaluation criteria for the upright position are suitable for the supine position. The purpose of this meta-analysis is to compare the differences in peak oxygen uptake (VO2peak) between upright and supine lower extremity bicycle exercise.Methods: We searched PubMed, Web Of Science and Embase from inception to March 27, 2021. Self-control studies comparing VO2peak between upright and supine were included. The quality of the included studies was assessed using a checklist adapted from published papers in this field. The effect of posture on VO2peak was pooled using random/fixed effects model.Results: This meta-analysis included 32 self-control studies, involving 546 participants (63% were male). 21 studies included only healthy people, 9 studies included patients with cardiopulmonary disease, and 2 studies included both the healthy and cardiopulmonary patients. In terms of study quality, most of the studies (n = 21, 66%) describe the exercise protocol, and we judged theVO2peak to be valid in 26 (81%) studies. Meta-analysis showed that the upright VO2peak exceeded the supine VO2peak [relative VO2peak: mean difference (MD) 2.63 ml/kg/min, 95% confidence interval (CI) 1.66-3.59, I2 = 56%, p < 0.05; absolute VO2peak: MD 0.18 L/min, 95% CI 0.10-0.26, I2 = 63%, p < 0.05). Moreover, subgroup analysis showed there was more pooled difference in healthy people (4.04 ml/kg/min or 0.22 L/min) than in cardiopulmonary patients (1.03 ml/kg/min or 0.12 L/min).Conclusion: VO2peak in the upright position is higher than that in supine position. However, whether this difference has clinical significance needs further verification.Systematic Review Registration: identifier, CRD42021233468.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
HLHyemin Lee
Hyemin Lee
CLCaiyue Li
Caiyue Li
Ji Hoon JungJi Hoon Jung
Ji Hoon Jung
YZYiwei Zhang
Yiwei Zhang
JWJieqiong Wang
Jieqiong Wang
HLHua Lu
Hua Lu
Coiled-coil domain containing 3 (CCDC3) was previously shown to regulate liver lipid metabolism as a secretory protein. Our recent studies revealed an intracellular role of CCDC3 as a tumor suppressor in breast cancer (BrC). Bioinformatics datasets analysis showed that CCDC3 is under-expressed in BrCs, while its higher levels are correlated with higher overall survival and lower relapse of cancer patients. CCDC3 is positively correlated with p53 and its target genes. Ectopic CCDC3 markedly suppressed proliferation, colony formation, and xenograft tumor growth by augmenting p53 activity in BrC cells. In contrast, knockdown of endogenous CCDC3 using CRISPR led to reduction of p53 level and activity, consequently promoting the proliferation of BrC cells. Mechanistically, CCDC3 bound to the C-termini of p53 and MDM2, consequently stabilizing p53 in the nucleus and impairing MDM2 recruitment of p53 to the 26S proteosome without inhibiting p53 ubiquitination. Also, knockdown of CCDC3 caused the resistance of BrC cells to 5-FU to some degrees by alleviating p53 response to this drug. p53 induced CCDC3 expression by binding to its promoter specifically in BrC cells. Our results unveil a unique mechanism underlying CCDC3 activation of p53 in a positive feedback fashion to suppress BrC growth and suggest that CCDC3 deficiency could be a factor for drug resistance of BrCs. Citation Format: Hyemin Lee, Caiyue Li, Ji Hoon Jung, Yiwei Zhang, Jieqiong Wang, Chang Liu, Allyson M. Segall, Roger L. Sheffmaker, Shelya X. Zeng, Hua Lu. Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 856.